Seguir
Matthias Scheffler
Matthias Scheffler
Lung Cancer Group Cologne, University Hospital of Cologne, Center for Integrated Oncology ABCD
Dirección de correo verificada de uk-koeln.de
Título
Citado por
Citado por
Año
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–pretreated non–small-cell lung cancer …
P Hoffknecht, A Tufman, T Wehler, T Pelzer, R Wiewrodt, M Schütz, ...
Journal of Thoracic Oncology 10 (1), 156-163, 2015
2642015
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors
S Ortiz-Cuaran, M Scheffler, D Plenker, L Dahmen, AH Scheel, ...
Clinical Cancer Research 22 (19), 4837-4847, 2016
2562016
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles
P Di Gion, F Kanefendt, A Lindauer, M Scheffler, O Doroshyenko, U Fuhr, ...
Clinical pharmacokinetics 50, 551-603, 2011
2242011
PubMed results
G Goeckenjan, H Sitter, M Thomas, D Branscheid, M Flentje, F Griesinger, ...
Pneumologie 65 (8), e51-e75, 2011
2172011
K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways
M Scheffler, MA Ihle, R Hein, S Merkelbach-Bruse, AH Scheel, ...
Journal of Thoracic Oncology 14 (4), 606-616, 2019
2012019
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18) F] fluorodeoxyglucose and [(18) F] fluorothymidine positron …
T Zander, M Scheffler, L Nogova, C Kobe, W Engel-Riedel, M Hellmich, ...
J Clin Oncol 29 (13), 1701-1708, 2011
2002011
Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort
O Gautschi, J Milia, B Cabarrou, MV Bluthgen, B Besse, EF Smit, J Wolf, ...
Journal of Thoracic Oncology 10 (10), 1451-1457, 2015
1972015
A genomics-based classification of human lung tumors
Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM),
Science translational medicine 5 (209), 209ra153-209ra153, 2013
1712013
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A Kron, C Alidousty, M Scheffler, S Merkelbach-Bruse, D Seidel, R Riedel, ...
Annals of oncology 29 (10), 2068-2075, 2018
1572018
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies
M Scheffler, M Bos, M Gardizi, K König, S Michels, J Fassunke, C Heydt, ...
Oncotarget 6 (2), 1315, 2015
1402015
Benchmarking of mutation diagnostics in clinical lung cancer specimens
S Querings, J Altmüller, S Ansén, T Zander, D Seidel, F Gabler, M Peifer, ...
PloS one 6 (5), e19601, 2011
1382011
Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
R Frank, M Scheffler, S Merkelbach-Bruse, MA Ihle, A Kron, M Rauer, ...
Clinical Cancer Research 24 (13), 3087-3096, 2018
1362018
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines
M Scheffler, P Di Gion, O Doroshyenko, J Wolf, U Fuhr
Clinical pharmacokinetics 50, 371-403, 2011
1362011
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
J Fassunke, F Müller, M Keul, S Michels, MA Dammert, A Schmitt, ...
Nature communications 9 (1), 4655, 2018
1252018
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
AH Scheel, S Ansén, AM Schultheis, M Scheffler, RN Fischer, S Michels, ...
Oncoimmunology 5 (5), e1131379, 2016
1172016
Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
F Malchers, F Dietlein, J Schöttle, X Lu, L Nogova, K Albus, ...
Cancer discovery 4 (2), 246-257, 2014
1172014
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
M Scheffler, A Schultheis, C Teixido, S Michels, D Morales-Espinosa, ...
Oncotarget 6 (12), 10577, 2015
1092015
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
F Skoulidis, KC Arbour, MD Hellmann, PD Patil, ME Marmarelis, ...
Journal of Clinical Oncology 37 (15_suppl), 102-102, 2019
1012019
Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients
K König, M Peifer, J Fassunke, MA Ihle, H Künstlinger, C Heydt, K Stamm, ...
Journal of Thoracic Oncology 10 (7), 1049-1057, 2015
1012015
Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial
S Michels, B Massutí, HU Schildhaus, J Franklin, M Sebastian, E Felip, ...
Journal of thoracic oncology 14 (7), 1266-1276, 2019
952019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20